We waited a long time for NAVB to have Lmyphoseek approved...and now that it has been approved, we just have to wait and see what CAH can do in terms of sales! Remember, NAVB wasn't making money, at least not a lot, and now it has a drug that can infuse cash! Plus, we have EMA approval pending and sNDA for the H&N trials that were highly positive.
I don't care about the activity of the stock at the moment, I know it's down $1.00/share since approval, but those are all traders and shorties...I'm an investor, and fundamentals win at the end instead of technical!
The shorts have pestered this stock for a long time. They said the trials were flawed and lymphoseak would not get FDA approval. They said the company only had one drug. They said NAVb would do a secondary. All their arguments were killed. They will have to close their trade and cover starting this year imo.
Day traders are taking a little profit every time we have a move up. With any positives news regarding EU approval & level acceptance of Lymphoseek, they will not continue to have impact on stock price & shorts will get hammered.
I beg to differ on the stock price not being impacted should we get news on H&N sNDA and EMA approval...although the shorts WILL get hammered should we get the news! People do not understand the impact the LYMPHOSEEK has...it will be the new standard-of-care, no more blue dye, no more sulfur colloid...just Lymphoseek. Who would use inferior detection injections?!?!
Check out the volumes, looks like we are all holding strong. The selling cup has run dry. The ceiling will crack, I'm just uncertain on the timing. As been noted continuously, this stock does not behave. It could be other institutions wanting a piece of the back room stock issue pie. That's all I can see...